BetaShares Gold Bullion ETF - Currency Hedged

QAU

QAU.AX was created on 2011-05-03 by BetaShares. The fund's investment portfolio concentrates primarily on gold commodities. The investment objective of the Fund is to provide an investment return, before fees and expenses, that closely tracks the performance of the price of gold bullion, with a currency hedge against movements in the AUD/USD exchange rate.

QBE Insurance Group Limited

QBE

QBE Insurance Group Ltd. engages in providing underwriting general insurance and reinsurance risks. The company is headquartered in Sydney, New South Wales and currently employs 13,479 full-time employees. The principal activities of the Company include underwriting general insurance and reinsurance risks, management of Lloyd's syndicates and investment management. The firm's segments include North America, International and Australia Pacific. The North America segment writes general insurance, reinsurance, and crop business in the United States. The International segment writes general insurance business in the United Kingdom, Europe, and Canada. This segment also writes general insurance and reinsurance business through Lloyd's; worldwide reinsurance business through offices in the United Kingdom, United States, Ireland, Bermuda, Dubai, and mainland Europe; and provides personal and commercial insurance covers in Hong Kong, Singapore, Malaysia, and Vietnam. The Company’s Australia Pacific segment primarily underwrites general insurance risks throughout Australia, New Zealand and the Pacific region.

PYC Therapeutics Limited

PYC

PYC Therapeutics Ltd is a AU-based company operating in Biotechnology industry. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The firm utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The firm's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.

Qualitas Limited

QAL

Qualitas Ltd. engages in real estate management services. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-12-16. The firm offers a range of investment solutions for institutional, wholesale and retail clients. The company offers flexible capital solutions for its partners, creating long term value for shareholders and the communities in which it operates. The firm is focused on real estate private credit, opportunistic real estate private equity, income-producing commercial real estate and build-to-rent residential. The firm has two segments: Funds Management and Direct Lending. The Funds Management segment includes all the Company’s core funds management activities and includes funds management fees, performance fees and other fee income. The company also includes dividends and distributions from its co-investment and direct lending activities. The Direct Lending segment relates to the interest income and expenses relating to activities undertaken by its wholly owned subsidiaries Arch Finance and Peer Estate.